Establishment and application of mouse model for FGFR2 (Fibroblast Growth Factor Receptor 2) expression monitoring and interaction molecule screening

By inserting tag sequences and reporter genes into the FGFR2 gene, a mouse model was constructed, which solved the problem of inaccurate detection of FGFR2 expression sites and difficulty in screening of interactive molecules, and realized FGFR2 expression monitoring and screening of interactive molecules for treatment FGFR2-related diseases provide new drug targets.

CN118910109APending Publication Date: 2024-11-08CHINESE PEOPLES LIBERATION ARMY ARMY SPECIAL MEDICAL CENTER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411092659.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to accurately detect the expression sites and interacting molecules of FGFR2 in vivo, and there is a lack of tools for large-scale screening of FGFR2 interacting molecules in vivo.

Method used

By inserting coding tag sequences and reporter genes into the coding region of the FGFR2 gene, a mouse model is constructed, and the tag sequences and reporter genes are integrated into the coding region of the FGFR2 gene using gene editing technology to monitor FGFR2 expression and screen interactive molecules.

Benefits of technology

A mouse model for FGFR2 expression monitoring and its interaction molecule screening was successfully prepared. It can accurately monitor FGFR2 expression in mice and screen out FGFR2 interacting molecules, providing a new drug target for the treatment of diseases caused by FGFR2 mutations. point.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910109A_ABST
    Figure CN118910109A_ABST
Patent Text Reader

Abstract

The invention provides a construction method of an animal model, which comprises the step of inserting a gene for coding a tag sequence and a reporter gene at a termination codon of a coding region of an FGFR2 (Fibroblast Growth Factor Receptor 2) gene, so that the animal model expresses an FGFR2 molecule fused with the tag sequence and the reporter gene. The invention successfully prepares a gene knock-in mouse (FGFR2-3 * Flag-2A-tdTomato mouse) for endogenous FGFR2 expression monitoring and endogenous FGFR2 interaction molecule screening, provides a mouse model for monitoring FGFR2 expression in a mouse body and screening endogenous FGFR2 interaction molecules, and detects the expression condition of FGFR2 in skull tissue cells by using the mouse model for the first time. FGFR2 interaction molecules in skull tissue cells are screened, and a new drug target is provided for screening and preparing drugs for treating diseases caused by FGFR2 mutation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of transgenic animal models, and in particular to the establishment and application of a mouse model for monitoring FGFR2 expression and screening its interacting molecules. Background Art

[0002] Fibroblast growth factors and their receptors (FGFs / FGFRs) are important signal regulatory molecules in the body, and are widely involved in organ development and pathological processes. In bone development, FGFs / FGFRs signals play a vital role, and their increased or decreased activity leads to skeletal abnormalities. FGFR2 is one of the important FGF receptors, located on the cell membrane. Extracellular FGF signaling molecules (FGF2, FGF7, FGF10, etc.) bind to FGFR2 with tyrosine kinase activity, causing FGFR2 to dimerize, and then activate a series of intracellular signaling molecules to phosphorylate, transmitting the signal into the cell. FGFR2 is mainly located on the cell membrane, including the extracellular region, transmembrane region and intracellular kinase region. Clinically, FGFR2 gain-of-function point mutations including Ser252Trp and Pro253Arg cause premature fontanelle syndrome (such as Apert, Crouzon, Pfeiffer, etc.), which manifests as skull deformity, widened eyes, facial dysplasia, short limbs, mental retardation, etc. In addition, FGFR2 transmembrane region loss-of-function mutations cause BBD (Bent Bone Dysplasia) syndrome, and patients show symptoms such as long bone curvature, craniofacial deformity and craniosynostosis.

[0003] FGFR2 plays a role in bone development, genetic diseases, and bone damage repair. It is very important to analyze the mechanism of action of FGFR2 in these processes. First, we need to understand the expression of endogenous FGFR2 in various parts of the skeletal organs. Only by clarifying the expression site of FGFR2 can we understand where it works. Currently, the expression of FGFR2 in tissues is mainly detected through in situ hybridization and immunohistochemistry. These technologies require tissues to be sliced ​​before detection, and cannot be observed in vivo. In addition, the false positive rate is relatively high, and it cannot fully and truly reflect the expression of FGFR2 in the body.

[0004] Secondly, we need to find out the molecules that interact with FGFR2 molecules in the body. Previous studies have shown that after the Ser252Trp or Pro253Arg mutation of FGFR2, the binding force between FGF ligand molecules and FGFR2 molecules is enhanced, and intracellular ERK1 / 2, P38, PI-3K and other signals are continuously activated, causing changes in target gene expression, which in turn leads to enhanced proliferation and differentiation of cranial suture mesenchymal cells, osteoblasts, etc., and accelerated cranial suture closure. Therefore, finding the interacting molecules of FGFR2 in mice can better analyze the mechanism of action of FGFR2. However, there is currently a lack of tool mice that can be used for large-scale screening of FGFR2 interacting molecules in the body for screening FGFR2 interacting molecules in bones. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides a mouse model for monitoring FGFR2 expression and screening its interacting molecules, and its application. It solves the problem of inaccurate detection of FGFR2 expression sites in the prior art, and provides a method for large-scale screening of FGFR2 interacting molecules in vivo.

[0006] In one aspect, the present invention provides a method for constructing an animal model, comprising inserting a gene encoding a tag sequence and a reporter gene at the stop codon of the coding region of the FGFR2 gene, so that the animal model expresses the FGFR2 molecule fused with the tag sequence and the reporter gene.

[0007] In one embodiment of the present invention, the tag sequence includes a His tag, a FLAG tag, a HA tag, a Myc tag, a GST tag, an MBP tag, and a Strep tag.

[0008] In a preferred embodiment of the present invention, the tag sequence is a FLAG tag.

[0009] In one embodiment of the present invention, the expression products of the reporter gene include green fluorescent protein (Green Fluorescent Protein, GFP), β-galactosidase (β-galactosidase, LacZ), firefly luciferase (Firefly Luciferase, Luc), Renilla luciferase (Renilla Luciferase, Rluc), red fluorescent protein (Red Fluorescent Protein, RFP), yellow-green fluorescent protein (Yellow Fluorescent Protein, YFP), and blue fluorescent protein (Blue Fluorescent Protein, BFP).

[0010] In a preferred embodiment of the present invention, the expression product of the reporter gene is a red fluorescent protein, and more preferably, the red fluorescent protein is TdTomato.

[0011] In one embodiment of the present invention, the gene encoding the tag sequence and the reporter gene are connected in series.

[0012] In a preferred embodiment of the present invention, a gene encoding a self-cleaving peptide is connected between the gene encoding the tag sequence and the reporter gene. The self-cleaving peptides include P2A (Porcine teschovirus-1 2A peptide), T2A (Thoseaasigna virus2A peptide), and F2A (Foot-and-mouth disease virus 2A peptide).

[0013] In one embodiment of the present invention, the method for inserting a gene encoding a tag sequence and a reporter gene at the termination codon of the coding region of the FGFR2 gene comprises: constructing a targeting vector containing the gene encoding the tag sequence and the reporter gene, and introducing the vector into ES cells, and integrating the gene encoding the tag sequence and the reporter gene into the termination codon of the coding region of the FGFR2 gene by a gene editing system.

[0014] In one embodiment of the present invention, the targeting vector comprises a 5' homology arm, a gene encoding a tag sequence and a reporter gene, and a 3' homology arm.

[0015] In one embodiment of the present invention, the sequence of the 5' homology arm is as shown in SEQ ID NO: 1 or a nucleotide sequence having at least 95% identity with the sequence shown in SEQ ID NO: 1. In one embodiment of the present invention, the sequence of the 3' homology arm is as shown in SEQ ID NO: 2 or a nucleotide sequence having at least 95% identity with the sequence shown in SEQ ID NO: 2.

[0016] In one embodiment of the present invention, the targeting vector comprises a 5' homology arm, 3*Flag-P2A-TdTomato, a FRT site, Poly A, Neo, a FRT site, and a 3' homology arm connected in series.

[0017] In one embodiment of the present invention, the introduction method is selected from the group consisting of: transformation, transfection, heat shock, electroporation, transduction, and microinjection.

[0018] In one embodiment of the present invention, the introduction method is a non-viral method.

[0019] In one embodiment of the present invention, the gene editing system is selected from traditional ES cell gene targeting, ZincFingerNucleases (ZFNs), CRISPR-Cas or Transcription Activator-Like EffectorNucleases (TALENs), preferably CRISPR-Cas or traditional ES cell gene targeting; more preferably traditional ES cell gene targeting.

[0020] In one embodiment of the present invention, the method for constructing the animal model comprises the following steps:

[0021] (1) Introducing the targeting vector into ES cells; (2) Screening positive ES cells; (3) Blastocyst injection and embryo transplantation of ES cells to obtain FGFR2 gene knock-in chimeric mice; (4) The chimeric mice are mated with C57BL / 6J pure strain mice to obtain ES cell-derived mice and FGFR2 gene knock-in heterozygous mice.

[0022] In one embodiment of the present invention, step (1) comprises: linearizing a targeting vector containing a gene encoding a tag sequence and a reporter gene and introducing the vector into ES cells, and integrating the gene encoding a tag sequence and the reporter gene into the stop codon of the FGFR2 gene coding region by homologous recombination.

[0023] In one embodiment of the present invention, the step (2) comprises: extracting genomic DNA of ES cells for genotype identification to obtain homologous recombinant ES cells.

[0024] In one embodiment of the present invention, steps (3) and (4) further include: extracting mouse genomic DNA and performing genotype identification using a PCR method to obtain positive mice with successful targeting.

[0025] In a second aspect, the present invention provides at least one of the following applications of the above-mentioned animal model:

[0026] (1) In vivo tracing of FGFR2; (2) Screening and identification of FGFR2 interacting molecules; (3) Screening of drugs for treating diseases caused by FGFR2 mutations.

[0027] In one embodiment of the present invention, the FGFR2 interacting molecules include one or more of ARID1B, GNAS, NPM1, ACTB, FN1, TPM2, YBX1, ALB, PPP2R1A, TPM1, KRT5, KRT14, PPHLN1, GFAP, ZEB1, KRT8, KRT19, SRSF1, HNRNPH1, EIF3H, NES, LOX, ACTC1, THBS1, GJA1, FLNA, SF1, VIM, NONO, EWSR1, KRT10, S100A4, HMGA2, ELAVL1, PLP1, DSP, KRT1, MBNL1, ANXA2, HNRNPL, PPIB, MAGOHB, TPM3, FLNB, LMNA, and SF3B1.

[0028] In one embodiment of the present invention, the disease includes cancer (such as breast cancer, gastric cancer, bladder cancer, endometrial cancer), hereditary diseases (premature closure of fontanelle syndrome, such as Crouzon Syndrome, Apert Syndrome, Muenke Syndrome, Pfeiffer Syndrome, Beare-Stevenson Cutis Gyrata Syndrome, BBD syndrome) and bone diseases (such as achondroplasia, bone damage repair).

[0029] In a third aspect, the present invention provides a method for screening FGFR2 interacting molecules, comprising using the above-mentioned animal model for screening.

[0030] In one embodiment of the present invention, the method for screening FGFR2 interacting molecules includes: isolating skull tissue cells of an animal model, extracting total protein, enriching FGFR2 interacting molecules by immunoprecipitation (IP) using the tag sequence of the FGFR2 molecule, and performing mass spectrometry analysis on the interacting molecules.

[0031] In a fourth aspect, the present invention provides the use of FGFR2 interacting molecules as drug targets in the preparation of drugs for treating diseases caused by FGFR2 mutations.

[0032] In one embodiment of the present invention, the FGFR2 interacting molecules include one or more of ARID1B, GNAS, NPM1, ACTB, FN1, TPM2, YBX1, ALB, PPP2R1A, TPM1, KRT5, KRT14, PPHLN1, GFAP, ZEB1, KRT8, KRT19, SRSF1, HNRNPH1, EIF3H, NES, LOX, ACTC1, THBS1, GJA1, FLNA, SF1, VIM, NONO, EWSR1, KRT10, S100A4, HMGA2, ELAVL1, PLP1, DSP, KRT1, MBNL1, ANXA2, HNRNPL, PPIB, MAGOHB, TPM3, FLNB, LMNA, and SF3B1.

[0033] In one embodiment of the present invention, the disease includes cancer (such as breast cancer, gastric cancer, bladder cancer, endometrial cancer), hereditary diseases (premature closure of fontanelle syndrome, such as Crouzon Syndrome, Apert Syndrome, Muenke Syndrome, Pfeiffer Syndrome, Beare-Stevenson Cutis Gyrata Syndrome, BBD syndrome) and bone diseases (such as achondroplasia, bone damage repair).

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] The present invention successfully prepared a gene knock-in mouse (FGFR2-3*Flag-2A-tdTomato mouse) for monitoring endogenous FGFR2 expression and screening its interacting molecules, providing a mouse model for monitoring FGFR2 expression and screening endogenous FGFR2 interacting molecules in mice. The mouse model was used for the first time to detect the expression of FGFR2 in skull tissue cells, and the FGFR2 interacting molecules in skull tissue cells were screened, providing a new drug target for screening and preparing drugs for treating diseases caused by FGFR2 mutations. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Schematic diagram of the preparation scheme for FGFR2 gene knock-in mice;

[0037] Figure 2 This is the constructed FGFR2 targeting vector plasmid;

[0038] Figure 3 is the expression of FGFR2 in the coronal suture and skull;

[0039] Figure 4 is the expression of FGFR2 in the sagittal suture and skull;

[0040] Figure 5 is the expression of FGFR2 in the lambdoid suture and skull;

[0041] Figure 6 is the expression of FGFR2 in the skull base;

[0042] Figure 7 This is the basepeak graph of mass spectrometry sequencing for FGFR2 interaction molecule detection;

[0043] Figure 8 Partial results of mass spectrometry sequencing screening of FGFR2 interacting molecules. DETAILED DESCRIPTION

[0044] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.

[0045] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0046] Example 1 Establishment of mouse model

[0047] 1. Donor vector construction

[0048] Through fragment amplification (5'arm, cKO, 3'arm) → connection (backbone + fragment) / transformation → bacterial detection → positive clone plasmid extraction → enzyme digestion identification → test → preparation of injection plasmid;

[0049] Fragment amplification (5'arm, cKO, 3'arm): Use Novozyme P515 high-fidelity enzyme to prepare a 50ul system for PCR amplification, 30 cycles; Gel recovery: Electrophoresis the PCR product and use Qiagen gel recovery kit (Cat. No.: 28706) to recover the gel at the position of the target product;

[0050] The sequence of the 5'arm is (SEQ ID NO: 1):

[0051]

[0052] The sequence of the 3'arm is (SEQ ID NO: 2):

[0053]

[0054] The structure of the cKO element is: 3*Flag-P2A-TdTomato, FRT site, Poly A, Neo, FRT site in series. The amplified fragment sequence is shown in SEQ ID NO:3.

[0055] Ligation (backbone pBasicFNeoF+fragment) / transformation: Use Novagen C115 ligase to connect the recovered fragments, use Takara's Stellar competent medium to transform the connected DNA fragments into Escherichia coli, and culture at 37°C overnight; Bacteria inspection: Pick 16 plaques with good morphology, use Novagen P222 Taq enzyme, prepare a 25ul system for PCR amplification; Pick plaques with correct bands, inoculate 4mL broth culture medium and shake for culture; Extract plasmids from positive clones: Use alkaline lysis method to extract plasmids; Enzyme digestion identification and sequencing: Select appropriate NEB endonucleases, prepare a 20ul enzyme digestion system with 600ng plasmid for enzyme digestion, and sequence the plasmids with correct enzyme digestion; Prepare plasmids for injection: For clones with correct sequencing results, inoculate 22.5mL broth culture medium overnight, use Qiagen's 27106 plasmid recovery kit to recover plasmids for injection. The preparation method of FGFR2 gene knock-in mice is as follows Figure 1 As shown; the constructed FGFR2 targeting vector plasmid is as shown Figure 2 shown.

[0056] 2. ES cell preparation, electroporation and drug screening

[0057] ES cells were cultured, trypsinized, and cell counts were performed to ensure that the number of cells was sufficient for electroporation. C57BL / 6N ES cells were revived and subcultured using mouse embryonic stem cell serum-free medium (OriCell, MUXES-90061). 1×10 7 After the cells were resuspended in electroporation buffer, 35 μg of linearized plasmid was added, mixed and placed on ice for 5 min. The cell suspension was transferred to an electroporation cup, and the electroporation parameters were 250V, 500 μF, and electroporation was performed once. The electroporated cells were transferred to a culture dish pre-inoculated with G418-resistant MEF cells, and mouse embryonic stem cell serum medium (OriCell, MUXES-90011) was used for subsequent culture. After 24 hours, the cells were screened with complete mouse embryonic stem cell culture medium containing G418 (final concentration 200 μg / mL) for 7 days, during which the cells were observed and the medium was changed every day. After the drug screening was completed, the surviving clones were picked into a 96-well plate, one clone per well, and the medium was changed every day for culture. On the third day after the clone was picked, the 96-well plate was propagated in two, and one of them was frozen after the cells were full. After the other cell was full, genomic DNA was extracted for subsequent PCR identification.

[0058] 3. Blastocyst injection

[0059] The blastocysts were obtained from the uterus of the donor mother mouse 3.5 days after mating; the blastocysts with good morphology and moderate developmental status were selected and transferred to the culture medium of the injection dish; the ES cells to be injected were transferred to the cell culture medium of the injection dish so that they were evenly arranged and had moderate density; the ES cells were sucked into the injection needle and injected into the blastocyst cavity one by one.

[0060] 4. Preparation of surrogate mice and embryo transplantation

[0061] Prepare pseudo-pregnant female mice: select fertile female mice of appropriate age and mate with male mice that have been sterilized after vasectomy to stimulate a series of pregnancy changes in the female mice to obtain pseudo-pregnant female mice, which will serve as surrogate mice after the fertilized eggs are genetically modified; transplant the blastocysts injected with ES cells into the uterus of the surrogate female mice; after the transplantation, place the surrogate female mice in a clean cage and keep them warm until they wake up and then return them to the cage for breeding; after the blastocyst transplantation is completed, wait for the chimeric mice to be born; one week after the mice are born, the mice can be numbered by clipping their claws and identified by PCR at the same time; three weeks after the mice are born, they can be raised independently in separate cages.

[0062] 5. Identification of F0 mice

[0063] Collect tissues of 1-2 week old mice (tail or toe tissues); lyse the tissues and extract the genome; use specific primers for the target gene for PCR amplification and electrophoresis detection to screen out offspring with exogenous gene integration; if homozygotes need to be obtained, the positive F1 from the same source may be mated with siblings, and the F2 generation mice born will have a 25% probability of being homozygous; screen out mice with expression of the target gene, establish a stable lineage, and record the lineage status and pedigree; the integrated mice are called founder mice, which can be passed on and established, and the protein expression level can be identified if necessary.

[0064] 6. Passaging and establishment of F1 mouse lines

[0065] The F1 mice born are identified, and the F0 that can be transmitted normally through the reproductive system has a 50% chance of carrying the integrated target gene in their offspring; the obtained F1 positive mice can be used for experiments and continued generation (can also be bred with Cre mice); if homozygotes need to be obtained, the positive F1 from the same source may be sibling mated, and the F2 generation mice born will have a 25% chance of being homozygous; mice expressing the target gene will be screened out, and a stable generation line will be established, and the generation situation and pedigree will be recorded at the same time.

[0066] Example 2 Application of Fgfr2 gene knock-in mouse model in bones

[0067] 1. Detection of FGFR2 expression in mouse cranial sutures, skull base bones and cartilage connections

[0068] FGFR2-3*Flag-P2A-tdTomato mice and wild-type (WT) mice of the same litter were killed by intraperitoneal injection of sodium pentobarbital. The skulls were removed and fixed with 4% PFA in a 4°C refrigerator for 24 hours. The samples were washed twice with ddH2O for 3 minutes each time. The samples were decalcified with 15% EDTA in a 4°C refrigerator for 2-5 days. After the skull softened, the samples were washed twice with ddH2O for 3 minutes each time. The samples were immersed in 30% sucrose solution for 24-72 hours, and the fresh sucrose solution was replaced 2-3 times during this period. The specimens were trimmed and the coronal suture, sagittal suture, lambdoid suture, and skull base were embedded with embedding agent and frozen sections were made at a thickness of 12 μm.

[0069] DAPI staining: frozen sections were placed in a 37°C oven for 10 min, then soaked in PBS buffer for 5 min, histochemically, etc. 0.1% DAPI solution was used to stain cells for 1 min, and the sections were sealed with 60% sucrose solution, and DAPI and tdTomato fluorescence was observed under a fluorescence microscope.

[0070] The mouse was used to observe the fluorescence of Tomato, reflecting the expression of FGFR2 in the skull and cranial sutures at different developmental stages. It was found that at embryonic day 18.5 and 5 days after birth, tdTomato was expressed in the periosteum, dura mater, skull osteoblasts, and osteocytes of the skull, and a small amount was expressed in the osteocytes of the osteoblastic tissue. Figure 3 )、Sagittal suture( Figure 4 ) and herringbone seam ( Figure 5 ) cells expressed tdTomato, indicating that FGFR2 is widely expressed in skull tissue. At the base of the skull, tdTomato fluorescence was widely distributed in bone tissue, including cancellous osteoblasts and osteocytes of the occipital bone, basesphenoid bone, and anterior sphenoid bone. However, at the cartilage junction of the skull base, tdTomato fluorescence was only distributed in chondrocytes in the resting and proliferative zones, and chondrocytes in the hypertrophic zone did not express tdTomato ( Figure 6 ).

[0071] 2. Isolation of skull cells and identification of FGFR2 interacting molecules by protein profiling

[0072] The skull tissue cells of newborn FGFR2-3*Flag-2A-tdTomato mice were isolated and immunoprecipitated (IP) with Flag-tagged protein fused to the C-terminus of FGFR2 molecule to enrich FGFR2 interacting molecules, which were then analyzed by mass spectrometry.

[0073] The method for screening FGFR2 interacting molecules in knock-in mice includes: isolating newborn FGFR2-3*Flag-2A-tdTomato mouse skull tissue cells, extracting total protein, using the Flag tag fused to the C-terminus of the FGFR2 molecule to perform IP enrichment of FGFR2 interacting proteins, and sending the protein sample to mass spectrometry sequencing. The mass spectrometry procedure is as follows: sample enzymatic hydrolysis: after the sample is reduced and alkylated, Trypsin is added and enzymatic hydrolysis is performed at 37°C for 20 hours. The enzymatic hydrolysis product is desalted and freeze-dried, redissolved in 0.1% FA solution, and stored at -20°C for use. Mass spectrometry analysis: Solution A is an aqueous solution of 0.1% formic acid, and solution B is an acetonitrile aqueous solution of 0.1% formic acid (acetonitrile is 84%). After the chromatographic column is equilibrated with 95% solution A, the sample is loaded onto the Trap column by an automatic sampler. The mass-to-charge ratios of peptides and peptide fragments were collected according to the following method: 20 fragment spectra (MS2 scan) were collected after each full scan, see the mass spectrometry sequencing basepeak peak diagram ( Figure 7 ). Based on the mass spectrometry sequencing results, we screened potential FGFR2 interacting molecules such as ARID1B ( Figure 8 ).

[0074] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.

[0075] Sequence Listing SEQ ID NO: 3

[0076]

Claims

1. A method for constructing an animal model, characterized in that: The method comprises inserting a gene encoding a tag sequence and a reporter gene at the termination codon of the coding region of the FGFR2 gene, so that the animal model expresses the FGFR2 molecule fused with the tag sequence and the reporter gene.

2. The method for constructing an animal model according to claim 1, characterized in that: The tag sequence includes His tag, FLAG tag, HA tag, Myc tag, GST tag, MBP tag, Strep tag; Preferably, the tag sequence is a FLAG tag; Preferably, the expression products of the reporter gene include green fluorescent protein (GFP), β-galactosidase (LacZ), firefly luciferase (Luc), Renilla luciferase (Rluc), red fluorescent protein (RFP), yellow-green fluorescent protein (YFP), and blue fluorescent protein (BFP); Preferably, the expression product of the reporter gene is red fluorescent protein, and more preferably, the red fluorescent protein is TdTomato.

3. The method for constructing an animal model according to claim 1, characterized in that: The gene encoding the tag sequence and the reporter gene are connected in series; Preferably, a gene encoding a self-cleaving peptide is connected between the gene encoding the tag sequence and the reporter gene. The self-cleaving peptide includes P2A (Porcine teschovirus-1 2A peptide), T2A (Thosea asigna virus 2A peptide), and F2A (Foot-and-mouth disease virus 2A peptide).

4. The method for constructing an animal model according to claim 1, wherein: The method of inserting a gene encoding a tag sequence and a reporter gene at the termination codon of the coding region of the FGFR2 gene comprises: constructing a targeting vector containing the gene encoding the tag sequence and the reporter gene, introducing the vector into ES cells, and integrating the gene encoding the tag sequence and the reporter gene into the termination codon of the coding region of the FGFR2 gene by a gene editing system; Preferably, the targeting vector comprises a 5' homology arm, a gene encoding a tag sequence and a reporter gene, and a 3' homology arm; Preferably, the sequence of the 5' homology arm is as shown in SEQ ID NO: 1 or a nucleotide sequence having at least 95% identity with the sequence shown in SEQ ID NO: 1; Preferably, the sequence of the 3' homology arm is as shown in SEQ ID NO: 2 or a nucleotide sequence having at least 95% identity with the sequence shown in SEQ ID NO: 2; Preferably, the targeting vector comprises a 5' homology arm, 3*Flag-P2A-TdTomato, a FRT site, Poly A, Neo, a FRT site, and a 3' homology arm connected in series.

5. The method for constructing an animal model according to claim 4, characterized in that: The introduction method is selected from the group consisting of transformation, transfection, heat shock, electroporation, transduction, and microinjection; Preferably, the introduction method is a non-viral method; Preferably, the gene editing system is selected from traditional ES cell gene targeting, Zinc Finger Nucleases (ZFNs), CRISPR-Cas or Transcription Activator-Like Effector Nucleases (TALENs), preferably CRISPR-Cas or traditional ES cell gene targeting; more preferably traditional ES cell gene targeting.

6. The method for constructing an animal model according to claim 4, characterized in that: The method comprises: (1) introducing a targeting vector into ES cells; (2) screening positive ES cells; (3) blastocyst injection and embryo transplantation of ES cells to obtain FGFR2 gene knock-in chimeric mice; (4) mating the chimeric mice with C57BL / 6J pure strain mice to obtain ES cell-derived mice and obtain FGFR2 gene knock-in heterozygous mice; Preferably, the step (1) comprises: linearizing a targeting vector containing a gene encoding a tag sequence and a reporter gene and introducing the vector into ES cells, and integrating the gene encoding a tag sequence and the reporter gene into the stop codon of the FGFR2 gene coding region by homologous recombination. Preferably, the step (2) comprises: extracting genomic DNA of ES cells for genotype identification to obtain homologous recombinant ES cells. Preferably, steps (3) and (4) further include: extracting mouse genomic DNA and performing genotype identification using a PCR method to obtain positive mice with successful targeting.

7. At least one of the following applications of the animal model obtained by the construction method according to any one of claims 1 to 6: (1) In vivo tracing of FGFR2; (2) Screening and identification of FGFR2 interacting molecules; (3) Screening of drugs for treating diseases caused by FGFR2 mutations; Preferably, the FGFR2 interacting molecules include ARID1B, GNAS, NPM1, ACTB, FN1, TPM2, YBX1, ALB, PPP2R1A, TPM1, KRT5, KRT14, PPHLN1, GFAP, ZEB1, KRT8, KRT19, SRSF1, HNRNPH1, EIF3H, NES, LOX, ACTC1, THBS1, GJA1, FLNA, SF1, VIM, NONO, EWSR1, KRT10, S100A4, HMGA2, ELAVL1, PLP1, DSP, KRT1, MBNL1, ANXA2, HNRNPL, PPIB, MAGOHB, TPM3, FLNB, LMNA, SF3B1; Preferably, the disease includes cancer, more preferably breast cancer, gastric cancer, bladder cancer, endometrial cancer; hereditary diseases, more preferably early closure of fontanelle syndrome, such as Crouzon Syndrome, Apert Syndrome, Muenke Syndrome, Pfeiffer Syndrome, Beare-Stevenson Cutis Gyrata Syndrome, BBD syndrome; bone diseases, more preferably achondroplasia, bone damage repair.

8. A method for screening FGFR2 interacting molecules, comprising screening using the animal model obtained by the construction method according to any one of claims 1 to 6.

9. A method for screening FGFR2 interacting molecules according to claim 8, characterized in that: The method for screening FGFR2 interacting molecules comprises: isolating skull tissue cells of an animal model, extracting total protein, enriching FGFR2 interacting molecules by immunoprecipitation (IP) using a tag sequence of the FGFR2 molecule, and performing mass spectrometry analysis on the interacting molecules.

10. Application of FGFR2 interacting molecules as drug targets in the preparation of drugs for the treatment of diseases caused by FGFR2 mutations.